Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Photothermic therapy with cuttlefish ink-based nanoparticles in combination with anti-OX40 mAb achieve remission of triple-negative breast cancer.
Momenzadeh N, Hajian S, Shabankare A, Ghavimi R, Kabiri-Samani S, Kabiri H, Hesami-Zadeh K, Shabankareh ANT, Nazaraghay R, Nabipour I, Mohammadi M. Momenzadeh N, et al. Among authors: hesami zadeh k. Int Immunopharmacol. 2023 Feb;115:109622. doi: 10.1016/j.intimp.2022.109622. Epub 2022 Dec 26. Int Immunopharmacol. 2023. PMID: 36577156
Genetically engineered fusion of allergen and viral-like particle induces a more effective allergen-specific immune response than a combination of them.
Sani MZ, Bargahi A, Momenzadeh N, Dehghani P, Moghadam MV, Maleki SJ, Nabipour I, Shirkani A, Akhtari J, Hesamizadeh K, Heidari S, Omrani F, Akbarzadeh S, Mohammadi M. Sani MZ, et al. Appl Microbiol Biotechnol. 2021 Jan;105(1):77-91. doi: 10.1007/s00253-020-11012-0. Epub 2020 Nov 20. Appl Microbiol Biotechnol. 2021. PMID: 33215260
Corrigendum to "Photothermic therapy with cuttlefish ink-based nanoparticles in combination with anti-OX40 mAb achieve remission of triple-negative breast cancer" [Int. Immunopharmacol. 115 (2023) 109622].
Momenzadeh N, Hajian S, Shabankare A, Ghavimi R, Kabiri-Samani S, Kabiri H, Hesami-Zadeh K, Shabankareh ANT, Nazaraghay R, Nabipour I, Mohammadi M. Momenzadeh N, et al. Among authors: hesami zadeh k. Int Immunopharmacol. 2023 Nov;124(Pt B):111035. doi: 10.1016/j.intimp.2023.111035. Epub 2023 Oct 18. Int Immunopharmacol. 2023. PMID: 37858486 No abstract available.
The role of lovastatin in the attenuation of COVID-19.
Karampoor S, Hesamizadeh K, Shams Z, Ghafari Novin A, Farahmand M, Zahednasab H, Mirzaei R, Zamani F, Hajibaba M, Bouzari B, Laali A, Tabibzadeh A, Hadi Karbalaie Niya M, Keyvani H. Karampoor S, et al. Int Immunopharmacol. 2021 Dec;101(Pt A):108192. doi: 10.1016/j.intimp.2021.108192. Epub 2021 Sep 24. Int Immunopharmacol. 2021. PMID: 34607230 Free PMC article.
A possible pathogenic correlation between neutrophil elastase (NE) enzyme and inflammation in the pathogenesis of coronavirus disease 2019 (COVID-19).
Karampoor S, Hesamizadeh K, Maleki F, Farahmand M, Zahednasab H, Mirzaei R, Banoun H, Zamani F, Hajibaba M, Tabibzadeh A, Bouzari B, Bastani MN, Laali A, Keyvani H. Karampoor S, et al. Int Immunopharmacol. 2021 Nov;100:108137. doi: 10.1016/j.intimp.2021.108137. Epub 2021 Sep 14. Int Immunopharmacol. 2021. PMID: 34536744 Free PMC article.
11 results